Cargando…

Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years

INTRODUCTION: HIV-1 plasma viral load during treatment can be highly variable. Thus, there is the need to find a measure of cumulative viremia that can be used to assess both the short- and long-term efficacy of highly active antiretroviral therapy (HAART). Here, we validate a measure of cumulative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lima, Viviane D, Sierra-Madero, Juan, Wu, Zunyou, Singer, Joel, Wood, Evan, Hull, Mark W, Harrigan, Paul Richard, Montaner, Julio SG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013478/ https://www.ncbi.nlm.nih.gov/pubmed/24805184 http://dx.doi.org/10.7448/IAS.17.1.18617

Ejemplares similares

Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings
por: Lima, Viviane D, et al.
Publicado: (2016)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime
por: Wood, Evan, et al.
Publicado: (2006)

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
por: Vesterbacka, Jan, et al.
Publicado: (2013)

Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study
por: Hayashi, Kanna, et al.
Publicado: (2014)

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
por: Gleason, Rudolph L., et al.
Publicado: (2015)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
por: Caro-Vega, Yanink, et al.
Publicado: (2018)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

The Effect of Efavirenz on Estradiol Metabolism in Transgender Women
por: Leinung, Matthew C., et al.
Publicado: (2019)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Viremia in human Cowpox virus infection
por: Nitsche, Andreas, et al.
Publicado: (2007)

Harm reduction in hospitals: is it time?
por: Rachlis, Beth S, et al.
Publicado: (2009)

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
por: Guillemi, Silvia A, et al.
Publicado: (2016)

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial
por: Dahourou, Désiré Lucien, et al.
Publicado: (2017)

Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
por: Harris, Marianne, et al.
Publicado: (2012)

Difficulty accessing crack pipes and crack pipe sharing among people who use drugs in Vancouver, Canada
por: Ti, Lianping, et al.
Publicado: (2011)

Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study
por: Wood, Evan, et al.
Publicado: (2006)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Police and public health partnerships: Evidence from the evaluation of Vancouver's supervised injection facility
por: DeBeck, Kora, et al.
Publicado: (2008)

Inability to access addiction treatment predicts injection initiation among street-involved youth in a Canadian setting
por: DeBeck, Kora, et al.
Publicado: (2016)

No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database
por: Napoli, Andrew A, et al.
Publicado: (2014)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Does efavirenz replacement improve neurological function in treated HIV infection?
por: Payne, B, et al.
Publicado: (2017)

Methamphetamine use and malnutrition among street-involved youth
por: Werb, Dan, et al.
Publicado: (2010)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

HIV/AIDS in Vancouver, British Columbia: a growing epidemic
por: McInnes, Colin W, et al.
Publicado: (2009)

Assessing the adoption of lopinavir/ritonavir oral pellets for HIV‐positive children in Zimbabwe
por: Pasipanodya, Briony, et al.
Publicado: (2018)

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
por: Lima, Viviane D., et al.
Publicado: (2015)

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
por: Lima, Viviane D., et al.
Publicado: (2017)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART
por: Hogg, Robert S, et al.
Publicado: (2006)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
por: Su, Bin, et al.
Publicado: (2019)

Efavirenz induces DNA damage response pathway in lung cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting
por: Montaner, Julio S.G., et al.
Publicado: (2014)

Structural factors associated with an increased risk of HIV and sexually transmitted infection transmission among street-involved youth
por: Marshall, Brandon DL, et al.
Publicado: (2009)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bek3dqaj8k6u5dqd9s3t62e4d8